Skip to content

Bringing together the means and resources to help tackle the world’s biggest health challenges

George Health’s portfolio of three businesses encompasses clinical development and drug commercialisation, medical devices and data technology, underpinned by exclusive access to the research and scientific expertise of world-leading medical research institute, The George Institute for Global Health.

According to the WHO, only 50% of patients in developed countries who suffer from chronic diseases adhere to treatment recommendations. In developing countries, when taken together with poor access to health care, lack of appropriate diagnosis and limited access to medicines, poor adherence is threatening any effort to tackle chronic conditions such as hypertension. Using a low dose can often achieve much of the benefits, while avoiding many of the side effects, from a particular medicine. Combining multiple medicines can ensure a high efficacy overall.

George Medicines

George Medicines uses the research base and scientific expertise of The George Institute for Global Health to pursue the late-stage development of its innovative, single-pill combination therapies. The business is building a strong and diversified pipeline with its lead candidate, GMRx2, in Phase III development for the initial treatment of hypertension and under investigation for the prevention of recurrent intracerebral haemorrhage (stroke). George Medicines is backed by leading life sciences venture capital firm Brandon Capital, whose expertise is directed toward supporting its portfolio companies along the path to commercialisation and Brandon BioCatalyst, the largest life sciences investment fund in Australia and New Zealand.

George Clinical offers scientific leadership in kidney & metabolic, oncology, cardiovascular, neurology and respiratory clinical research. During its 20 years managing Phase I-IV clinical trials, more than 300,000 patients have been involved in more than 500 global studies.

George Clinical

Founded in the Asia-Pacific and driven by scientific expertise and operational excellence, George Clinical’s mission is to improve the health of millions of people worldwide through clinical research supported by global service delivery, world-class scientific leadership and therapeutic specialties. George Clinical is a leading contract research organisation (CRO), headquartered in Sydney, Australia, with more than 400 people providing the full range of clinical trial services to pharmaceutical, medical device and diagnostic customers, for all trial phases, registration and post-marketing trials. George Clinical combines scientific and clinical leadership with expert trial delivery to create distinctive world-class solutions. George Clinical and the George Institute for Global Health’s partnership enables operationally-supported, internationally-recognised scientific leadership and an extensive series of investigator networks, which allows George Clinical to provide customisable, clinical trial excellence from trial design through all aspects of delivery.

16 million people need dialysis treatment for kidney failure today. Only four million can afford it. The other 12 million die prematurely. Dialysis has been a safe and effective treatment for kidney failure for over 70 years, but is expensive, at over US$50,000 per patient per year.

Ellen Medical Devices

Ellen Medical Devices was formed to make dialysis affordable and accessible to millions of people who currently die prematurely from chronic kidney disease. In 2017, Ellen Medical Devices was a finalist in the Eureka Awards, Australia’s most prestigious science awards, recognising its affordable point-of-care dialysis system and in 2018, the Company was awarded $2.2 million from the NSW Medical Devices Fund. The Company’s dialysis system overcomes the critical barrier to affordable dialysis – the lack of cheap, sterile water in countries where the electricity supply is unreliable and water sources may be contaminated. Using a standard solar panel, it heats water taken from any local source to make steam, which is used to sterilise the water as well as to fill empty peritoneal dialysis (PD) bags under sterile conditions. The first clinical trial of Ellen Medical Devices’ dialysis system in human subjects has received ethics approval and will commence in 2022.